Entinostat, a selective class I HDAC inhibitor, is being tested in combination with nivolumab (anti-PD-1) in a phase II study for patients with metastatic cholangiocarcinoma and pancreatic cancer (NCT03250273). This evidence concerns the gene HDAC9 and pancreatic neoplasm.